Browse our 1,000+ Publications​

Latest Publications

Consensus Recommendations for CAR T-Cell Administration in Adult Acute Lymphoblastic Leukemia: a Modified Delphi Study

Muffly L, et al.
Blood
May 2026
Authors and Affiliates
Lori Muffly 1, Noelle V Frey 2, Gregory W Roloff 3, Jae H Park 4, Bhagirathbhai Dholaria 5, Anjali S Advani 6, Veronika Bachanova 7, Ryan D Cassaday 8, Michael Daunov 9, Kaitlyn C Dykes 10, Vivian Irizarry Gatell 11, Michael R Grunwald 12, Talal Hilal 13, LaQuisa C Hill 14, Omer Jamy 15, Vamsi K Kota 16, Muthu Kumaran 17, Chenyu Lin 18, Aaron C Logan 19, Marlise R Luskin 20, Kristen M O'Dwyer 21, Caspian Oliai 22, Olalekan O Oluwole 5, Joshua P Sasine 23, Marc S Schwartz 24, Melhem M Solh 25, Wendy Stock 26, Stephanie B Tsai 27, Matthew L Ulrickson 28, Sumithira Vasu 29, Eunice S Wang 30, Fevzi Firat Yalniz 31, Stephen A Strickland 32, Jessica T Leonard 33, Bijal D Shah 34, Ibrahim Aldoss 35 1Stanford University, Stanford, California, United States. 2Hospital of the University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States. 3The University of Chicago, Chicago, Illinois, United States. 4Memorial Sloan-Kettering Cancer Center, New York, New York, United States. 5Vanderbilt University Medical Center, Nashville, Tennessee, United States. 6Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States. 7University of Minnesota, Minneapolis, Minnesota, United States. 8University of Washington, Seattle, Washington, United States. 9University Hospitals Cleveland Medical Center and Case Western Reserve University, Cleveland, Ohio, United States. 10University of California, San Diego, La Jolla, California, United States. 11UT Southwestern, Dallas, Texas, United States. 12Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, United States. 13Mayo Clinic, Phoenix, Arizona, United States. 14Baylor College of Medicine, Houston, Texas, United States. 15University of Alabama at Birmingham, Birmingham, Alabama, United States. 16Georgia Cancer Center at Augusta University, Augusta, Georgia, United States. 17University of Arkansas Medical Center, Little Rock, Arkansas, United States. 18Duke University School of Medicine, Durham, North Carolina, United States. 19University of California San Francisco, San Francisco, California, United States. 20Dana-Farber Cancer Institute, Boston, Massachusetts, United States. 21University of Rochester School of Medicine and Dentistry, Rochester, New York, United States. 22Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States. 23Cedars-Sinai Medical Center, Los Angeles, California, United States. 24University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States. 25The Blood and Marrow Transplant Program at Northside Hospital, Atlanta, Georgia, United States. 26University of Chicago, Chicago, Illinois, United States. 27Loyola University Medical Center, Maywood, Illinois, United States. 28Banner MD Anderson Cancer Center, Gilbert, Arizona, United States. 29The Ohio State University, Columbus, Ohio, United States. 30Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States. 31University of Kentucky, Lexington, Kentucky, United States. 32SCRI at TriStar Centennial, Nashville, Tennessee, United States. 33Oregon Health Sciences, Portland, Oregon, United States. 34Moffitt Cancer Center, Tampa, Florida, United States. 35City of Hope National Medical Center, Duarte, California, United States.

Brexucabtagene autoleucel consolidation in adult B-cell acute lymphoblastic leukemia: real-world efficacy and toxicity

Jain N, et al.
Blood
May 2026
Authors and Affiliates
Nitin Jain 1, Niranjan Khaire 1, Nicholas Short 1, Shilpa Paul 1, Alexandra Lovell 1, Jayastu Senapati 1, Hannah Goulart 1, Gautam Borthakur 1, Tapan Kadia 1, Koichi Takahashi 1, Naveen Pemmaraju 1, Naval Daver 1, Ghayas Issa 1, Musa Yilmaz 1, Fadi G. Haddad 1, Wei-Ying Jen 1, Rabiul Islam 1, Rebecca Garris 1, Sa Wang 2, Beenu Thakral 2, Partow Kebriaei 3, Bouthaina Dabaja 4, Elizabeth Shpall 3, Sattva Neelapu 5, William Wierda 1, Guillermo Garcia-Manero 1, Farhad Ravandi 1, Hagop Kantarjian 1, Elias Jabbour1 1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 2Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 3Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX 4Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 5Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

Post CAR-T Measurable Residual Disease Monitoring in Mantle Cell Lymphoma Enables Early Detection of Disease Relapse

Ananth S, et al.
Am J Hematol
May 2026
Authors and Affiliates
Snegha Ananth1,2 | Neha Agarwal1 | Bita Sahaf1 | Allison Jacob3 | Lik Wee Lee3 | Heidi Simmons3 | Ilan Kirsch3 | Sushma Bharadwaj1 | Wen-kai Weng1 | Melody Smith1 | Saurabh Dahiya1 | David Miklos1 | Matthew J. Frank1 1Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, California, USA | 2University of Nebraska Medical Center, Omaha, Nebraska, USA | 3Adaptive Biotechnologies, Seattle, Washington, USA

Peripheral blood cfDNA detection using clonoSEQ assay in multiple myeloma is concordant with bone marrow and clinical biomarkers

Wiedmeier-Nutor J, et al.
Blood Cancer Journal
April 2026
Authors and Affiliates
J E Wiedmeier-Nutor 1, H E Kosiorek 2, M Arribas 3, H Simmons 4, A Jacob 4, S S Bhattu 3, R Fonseca 5, L Bruins 3, G Ahmann 3, U Yadav 3, S Chhabra 3, P L Bergsagel 3, R Fonseca 3 1Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA. Wiedmeier.julia@mayo.edu. 2Department of Quantitative Health Sciences, Mayo Clinic, Phoenix, AZ, USA. 3Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA. 4Adaptive Biotechnologies, Seattle, WA, USA. 5Department of Internal Medicine, Mayo Clinic, Phoenix, AZ, USA.

Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial

Nadeem O, et al.
Nature Medicine
April 2026
Authors and Affiliates
Omar Nadeem 1,2,3,10, David M. Cordas dos Santos 1,2,10, Sarah Nikiforow2, Anna Bosch-Vilaseca2, Elizabeth O’Donnell1,2, Robert Redd4, Kevin C. DeBraganca5, Adam S. Sperling 2,6, Yuxin Liu1,2, Caleb McEntire6, Frances Arters1,2, Colin O’Donnell3, Brendan Kineavy3, Marjorie Marto1,2, Amy Bergeron1,2, Emilie Swenson3, Kristin McHugh3, Abigail Caron3, Quentin Berry3, Hope Wei 3, Emily Durlacher 3, Elizabeth Grimm3, Francesco Corrado1,2, Nayda Bidikian1,2, Rocio Montes de Oca7, Tamar Lengil8, Denise De Wiest8, Casey Gervais2, Kevin Panaro 2, Eric L. Smith 2, Kenneth Anderson 2, Caron Jacobson2, Nikhil C. Munshi 2, Paul Richardson2, Deepu Madduri8, Jordan M. Schecter8, Craig Tendler8, Mark A. Wildgust8, Lorenzo Trippa4, Maria Victoria Mateos 9, Jerome Ritz 2 & Irene M. Ghobrial 1,2 1Center for Early Detection and Interception of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA, USA. 2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. 3Immune Effector Cell Therapy Program, Dana-Farber Cancer Institute, Boston, MA, USA. 4Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA. 5Janssen Research & Development, Raritan, NJ, USA. 6Brigham and Women’s Hospital, Boston, MA, USA. 7Johnson & Johnson, Spring House, PA, USA. 8Johnson & Johnson, Raritan, NJ, USA. 9Instituto de Investigación Biomédica de Salamanca (IBSAL), Hospital Universitario de Salamanca, Salamanca, Spain. 10These authors contributed equally: Omar Nadeem, David M. Cordas dos Santos.

Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial

Gay F, et al.
Nature Medicine
April 2026
Authors and Affiliates
Francesca Gay  1 , Wilfried Roeloffzen  2 , Meletios A. Dimopoulos  3,4, Laura Rosiñol  5 , Marjolein van der Klift6 , Roberto Mina  1 , Albert Oriol  7 , Eirini Katodritou8 , Ka Lung Wu9 , Paula Rodríguez Otero10, Roman Hájek11,12, Elisabetta Antonioli13, Mark van Duin14, Mattia D’Agostino1 , Joaquín Martínez-López  15, Elena M. van Leeuwen-Segarceanu16, Elena Zamagni17,18, Niels W. C. J. van de Donk  19, Katja C. Weisel  20, Luděk Pour21, Jakub Radocha22, Angelo Belotti23, Fredrik Schjesvold  24,25, Joan Bladé  4 , Hermann Einsele  26, Pieter Sonneveld  14,27, Mario Boccadoro28 & Annemiek Broijl14 1 Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy. 2 Department of Hematology, University Medical Center Groningen, Groningen, the Netherlands. 3 Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Athens, Greece. 4 Department of Medicine, Korea University, Seoul, South Korea. 5 Amyloidosis and Myeloma Unit, Department of Hematology, Hospital Clínic de Barcelona, IDIBAPS, and PETHEMA/GEM, Barcelona, Spain. 6 Department of Internal Medicine, Amphia Hospital, Breda, the Netherlands. 7 Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona, Spain. 8 Department of Hematology, Theagenion Cancer Hospital, Thessaloniki, Greece. 9 ZAS Cadix, Antwerp, Belgium. 10Cancer Center Clínica Universidad de Navarra, Pamplona, Spain. 11Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic. 12Department of Haematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic. 13Hematology Unit, AOU Careggi, Florence, Italy. 14Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. 15Hematology Department, Hospital Universitario de Octubre, Medicine Department Complutense University, imas12, CNIO, Madrid, Spain. 16Department of Hematology, St. Antonius Hospital, Nieuwegein, the Netherlands. 17IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia ‘Seràgnoli’, Bologna, Italy. 18Department of Medical and Surgical Sciences, Bologna University School of Medicine, Bologna, Italy. 19Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, the Netherlands. 20Department of Oncology, Hematology and BMT, University Medical Center of Hamburg-Eppendorf, Hamburg, Germany. 21Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic. 224th Department of Internal Medicine-Hematology, University Hospital Hradec Kralove, Charles University, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czech Republic. 23Department of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy. 24Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway. 25KG Jebsen Center for B cell malignancies, University of Oslo, Oslo, Norway. 26Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany. 27European Myeloma Network (EMN), Rotterdam, the Netherlands. 28European Myeloma Network (EMN), Turin, Italy

Final clinical data of a phase 1 dose-escalation study ofWVT078, a BCMA£CD3 bispecific antibody, alone and incombination with γ-secretase inhibitor WHG626 in patientswith relapsed and/or refractory multiple myeloma

Schjesvold F, et al.
Cancer
April 2026
Authors and Affiliates
Fredrik Schjesvold MD, PhD1,2 | Andrew Spencer MBBS, FRACP, FRCPA, DM3 |Yael C. Cohen MD4,5 | Enrique M. Ocio MD, PhD6 | Jordi Lopez-Pardo MD7 |Anna Maria Cafro MD8 | Natalie S. Callander MD9 | Jonathan L. Kaufman MD10 |Meera Mohan MD, MS11 | Martin Wermke MD12 | Noriko Doki PhD, MD13 |Rebecca Kan MPH14 | Pedro Milanez-Almeida PhD14 | Andrew Stein PhD14 |Gina Trabucco MSc14 | Stan Ye PhD14 | Karolina Kulec MSc15 |Romain Sechaud PhD16 | Souvik Banerjee PhD17 | Huiqin Zhong PhD18 |Clinton Lai MBChB, FFPM18 | Philipp J. Rauch MD16 | Marc S. Raab MD191Oslo Myeloma Center, Department of Hematology, OSLO University Hospital, Oslo, Norway2KG Jebsen Center for B Cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway3The Alfred Hospital, Monash University, Melbourne, Victoria, Australia4Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel5Hematology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel6Hospital Universitario Marqués de Valdecilla, Idival, Santander, Spain7Hospital de la Santa Creu i Sant Pau, Barcelona, Spain8Department of Hematology, GOM Niguarda Hospital, Milan, Italy9Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin, USA10Winship Cancer Institute, Emory University, Atlanta, Georgia, USA11Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA12NCT/UCC Early Clinical Trial Unit, Universitatsklinikum Carl Gustav Carus an der Technische Universitat, Dresden, Germany13Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan14Novartis Biomedical Research, Cambridge, Massachusetts, USA15Novartis Ireland Limited, Dublin, Ireland16Novartis Biomedical Research, Basel, Switzerland17Novartis Healthcare Pvt, Ltd, Hyderabad, India18Novartis Institutes for BioMedical Research, Shanghai, China19Heidelberg Myeloma Center Department of Medicine V, Medical Faculty and University Hospital, Heidelberg, Germany

Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial

Dytfeld D, et al.
Lancet Haematology
April 2026
Authors and Affiliates
Dominik Dytfeld 1, Tomasz Wróbel 2, Krzysztof Jamroziak 3, Tadeusz Kubicki 1, Paweł Robak 4, Anna Puła 5, Adam Walter-Croneck 6, Jarosław Czyż 7, Agata Tyczyńska 8, Agnieszka Druzd-Sitek 9, Krzysztof Giannopoulos 10, Adam Nowicki 11, Tomasz Szczepaniak 12, Anna Łojko-Dankowska 1, Magdalena Matuszak 1, Lidia Gil 1, Bartosz Puła 13, Justyna Rybka 2, Maciej Majcherek 2, Lidia Usnarska-Zubkiewicz 2, Łukasz Szukalski 7, Agnieszka Końska 14, Jan Maciej Zaucha 8, Jan Walewski 9, Damian Mikulski 4, Olga Czabak 10, Tadeusz Robak 15, Oscar B Lahoud 16, Jeffrey A Zonder 17, Jennifer H Cooperrider 18, Benjamin A Derman 18, Theodore Karrison 18, Andrzej J Jakubowiak 19 1Poznan University of Medical Sciences, Poznan, Poland. 2Wroclaw Medical University, Wroclaw, Poland. 3Medical University of Warsaw, Warsaw, Poland. 4Medical University of Lodz, Lodz, Poland. 5Medical University of Lodz, Lodz, Poland; University of Chicago, Chicago, IL, USA. 6Medical University of Lublin, Lublin, Poland; Department of Haematology and Bone Marrow Transplantation Centre of Oncology of the Lublin Region St Jana z Dukli, Lublin, Poland. 7Department of Haematology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Torun, Poland. 8Department of Haematology and Transplantology, Medical University of Gdansk, University Clinical Center Gdansk, Gdansk, Poland. 9Maria Skłodowska-Curie National Research Institute of Oncology, ERN EuroBloodNet, Warsaw, Poland. 10Medical University of Lublin, Lublin, Poland. 11Greater Poland Cancer Centre, Poznan, Poland. 12Poznan University of Medical Sciences, Poznan, Poland; St James's Hospital, Dublin, Ireland. 13Institute of Haematology and Blood Transfusion, Warsaw, Poland; Department of Haematology, Medical University of Lodz, Lodz, Poland. 14Institute of Haematology and Blood Transfusion, Warsaw, Poland. 15Department of Haematology, Medical University of Lodz, Lodz, Poland. 16NYU Langone Health, Perlmutter Cancer Center, New York, NY, USA; New York University Grossman School of Medicine, New York, NY, USA. 17Wayne State University Karmanos Cancer Institute, Detroit, MI, USA. 18University of Chicago, Chicago, IL, USA. 19University of Chicago, Chicago, IL, USA. Electronic address: ajakubowiak@medicine.bsd.uchicago.edu.

Daratumumab plus VRd in Japanese transplant‑ineligible/deferred NDMM patients: Japanese subgroup of the CEPHEUS trial

Suzuki K, et al.
International Journal of Hematology
March 2026
Authors and Affiliates
Kenshi Suzuki1 · Morio Matsumoto2 · Hiroyuki Takamatsu3 · Hiroshi Kosugi4 · Tadakazu Kondo5 · Tomoaki Fujisaki6 · Thierry Facon7 · Sonja Zweegman8 · Miku Ito9 · Chika Sakai9 · Satoshi Kanai9 · Tomohiko Nakatogawa9 · Melissa Rowe10 · Robin Carson11 · Saad Z. Usmani12 Department of Hematology, Japanese Red Cross Medical Center, 4‑1‑22 Hiroo, Shibuya‑ku, Tokyo 150‑8935, Japan 2 Department of Hematology, NHO Shibukawa Medical Center, Gunma, Japan 3 Department of Hematology, Kanazawa University Hospital, Ishikawa, Japan 4 Department of Hematology, Ogaki Municipal Hospital, Gifu, Japan 5 Department of Hematology, Kobe City Medical Center General Hospital, Hyogo, Japan 6 Department of Hematology, Matsuyama Red Cross Hospital, Ehime, Japan 7 Service des Maladies du sang, Hôpital Claude Huriez, Centre Hospitalier Universitaire de Lille, Lille, France 8 Department of Hematology, Cancer Center Amsterdam, Vrije Universiteit Medical Center, Amsterdam, The Netherlands 9 Johnson & Johnson, Tokyo, Japan 10 Johnson & Johnson, High Wycombe, UK 11 Johnson & Johnson, PA, USA 12 Memorial Sloan Kettering Cancer Center, New York, NY, USA

Isatuximab, bortezomib, lenalidomide, dexamethasone for multiple myeloma: dynamics of MRD-negativity in the IMROZ study

Orlowski R, et al.
Blood
February 2026
Authors and Affiliates
Robert Orlowski (The University of Texas MD Anderson Cancer Center, United States) Meletios Dimopoulos (Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece, Department of Medicine, Korea University, Seoul, Republic of Korea, Greece) Xavier Leleu (Hopital La Miletrie, France) Thierry Facon (Centre Hospitalier Universitaire (CHU) Lille, Service des Maladies du Sang, University of Lille, France) Tadao Ishida (Japanese Red Cross Medical Center, Japan) Roman Hajek (University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Czech Republic) Ivan Spicka (Charles University and General Faculty Hospital, Prague, Czech Republic) Joanna Romejko-Jarosinska (Marie Sklodowska-Curie National Research Institute of Oncology, Poland) Vladimir Vorobyev (S.P. Botkin Hospital, Russian Federation) Britta Besemer (University Hospital of Tuebingen, Germany) Sevgi Kalayoglu Besisik (Istanbul University Istanbul Medical Faculty, Turkey) Pawel Robak (Medical University of Łódź, Łódź, Poland, Poland) Tomas Jelínek (University Hospital Ostrava, Czech Republic) Hartmut Goldschmidt (Universitätsklinikum Heidelberg, Med. Klinik V, GMMG-Studygroup, Germany) Thomas Martin (University of California, San Francisco, United States) Mohamad Mohty (Hôpital Saint-Antoine, INSERM UMRs 938, and Université Sorbonne, France) Sandrine Macé (Sanofi, France) Ercem Kodas (Sanofi, France) Christina Tekle (Sanofi, United States) Andrea Shafer (Sanofi, United States) Philippe Moreau (Hematology, University Hospital Hôtel-Dieu, France)
Previous Next